Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer

STUDY NAME	TARGET ANTIGEN	VACCINE NAME/TYPE	CANCER
IMPACT	PAP	Mo/DCsPAP-GM-CSF	mCRPC
PROSPECT	PSA	PSA-TRICOM	mCRPC
Stimuvax	MUC1	BLPD25	NSCLC
PANVAC	MUC1/CEA	DCsPSA-TRICOM	Colorectal
GVAX	multiple	T47D&SKBR3 lines	Breast
DERMA	MAGE-A3	Rec Protein	Melanoma
MAGRIT	MAGE-A3	Rec Protein	NSCLC
IMPRINT	11 tumour peptides	soluble	Renal
TG4010	MUC1	MVA MUC-1-IL-2	Prostate NSCLC
CDX110	EGFRvIII	Soluble 13-mer	Glioblastoma

PAP: prostatic acid phosphatase, PSA: prostatic specific antigen, mCRPC: metastatic castrate-resistant prostate cancer, NSCLC: non-small cell lung cancer, Mo/Ds: monocyte/dendritic cells, TRICOM: triad costimulatory molecules, MUC1: mucin 1, MVA: modified vaccinia Ankara virus

References

Authors

Metrics

Articles in this issue

DOI: https://doi.org/10.1515/fco-2016-0005 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X

Journal RSS Feed

Language: English

Page range: 4 - 16

Submitted on: Feb 24, 2016

Accepted on: Aug 4, 2016

Published on: Sep 17, 2016

Published by: Helenic Society of Medical Oncology

In partnership with: Paradigm Publishing Services

Keywords:

Cancer immunotherapy,

Tumor infiltrating lymphocytes,

Immunoscore,

Cancer vaccines,

Checkpoint inhibitors

Related subjects:

Medicine,

Clinical medicine,

Internal medicine,

Haematology, oncology

© 2016 Nikolaos F. Pistamaltzian, Sonia A. Perez, Constantin N. Baxevanis, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 7 (2016): Issue 1 (March 2016)